BioLargo (BLGO) stock price, revenue, and financials

BioLargo market cap is $40.2 m, and annual revenue was $1.86 m in FY 2019

$40.2 M

BLGO Mkt cap, 21-Jul-2020

$439 K

BioLargo Revenue Q1, 2020
BioLargo Gross profit (Q1, 2020)179 K
BioLargo Gross profit margin (Q1, 2020), %40.8%
BioLargo Net income (Q1, 2020)-2.6 M
BioLargo EBIT (Q1, 2020)-1.7 M
BioLargo Cash, 31-Mar-2020744 K
BioLargo EV44.2 M

BioLargo Revenue

BioLargo revenue was $1.86 m in FY, 2019

Embed Graph

BioLargo Income Statement

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Revenue

12.2k120.5k30.8k13.8k10.5k14.4k120.0k18.4k9.3k21.1k16.4k26.7k39.8k13.9k39.0k162.3k46.0k100.0k172.0k263.0k326.7k277.0k364.0k426.0k534.0k439.0k

Cost of goods sold

3.9k12.7k17.8k8.1k6.9k6.2k9.0k8.4k2.5k8.9k7.7k6.4k7.7k19.9k6.1k15.8k47.1k22.5k73.4k123.3k163.2k200.9k121.5k192.0k260.0k

Gross profit

8.3k107.8k13.0k5.8k3.6k8.2k111.0k10.0k6.8k12.2k8.7k20.3k32.2k7.9k23.2k115.2k23.5k26.6k48.8k99.8k125.8k155.5k172.0k179.0k

Gross profit Margin, %

68%89%42%42%35%57%93%54%73%58%53%76%81%56%60%71%51%27%28%38%39%56%47%41%

R&D expense

12.1k9.0k16.3k43.8k54.5k51.4k147.1k267.9k163.6k129.4k187.0k138.0k167.2k162.3k351.1k330.0k348.6k391.3k324.3k425.7k521.7k425.6k443.4k426.0k367.0k332.0k335.0k

General and administrative expense

719.0k580.5k700.4k1.5m828.4k596.8k475.3k536.0k607.4k948.7k652.4k560.5k859.3k1.5m930.9k923.6k989.2k1.1m1.2m1.1m1.2m1.3m1.4m1.4m1.3m1.8m1.5m

Operating expense total

733.9k590.9k718.1k1.6m883.2k651.0k625.1k806.6k773.7k1.1m842.1k701.3k1.0m1.6m1.3m1.3m1.3m1.5m1.5m1.6m1.7m1.8m1.8m1.8m1.7m2.2m1.9m

Depreciation and amortization

2.7k1.3k1.3k311.0312.02.7k2.7k2.7k2.7k2.7k2.7k2.7k2.7k2.7k2.8k3.0k7.9k6.5k6.6k10.3k12.5k13.4k16.0k16.0k17.0k

EBIT

(725.6k)(483.0k)(705.0k)(1.6m)(879.5k)(642.8k)(514.1k)(796.6k)(766.9k)(1.1m)(833.4k)(681.0k)(997.0k)(1.6m)(1.3m)(1.2m)(1.2m)(1.4m)(1.5m)(1.5m)(1.6m)(1.6m)(1.7m)(1.5m)(1.9m)(1.7m)

EBIT margin, %

(5939%)(401%)(2288%)(11376%)(8384%)(4475%)(428%)(4325%)(8258%)(5068%)(5067%)(2553%)(2502%)(9158%)(3163%)(755%)(3109%)(1467%)(873%)(609%)(499%)(457%)(349%)(353%)(388%)

Interest expense

166.5k228.6k215.9k202.0k36.1k2.5k235.5k247.3k265.6k

Net Income

(892.1k)(711.7k)(921.0k)(1.8m)(915.7k)(645.3k)(538.8k)(698.5k)(1.0m)(1.1m)(826.5k)(780.4k)(1.3m)(2.4k)(1.6m)(1.7m)(2.5m)(2.1m)(2.5m)(2.2m)(2.4m)(3.6m)(2.4m)(2.7m)(2.0m)(3.9m)(2.6m)

BioLargo Balance Sheet

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Cash

243.8k189.6k310.6k515.3k427.8k91.0k67.7k53.5k363.4k318.3k151.7k227.4k96.9k560.2k1.0m889.0k1.7m1.2m433.5k1.3m921.9k651.1k533.5k512.0k706.0k2.1m744.0k

Accounts Receivable

7.6k10.3k17.8k12.1k7.3k8.4k14.9k1.3k4.4k2.9k4.7k7.4k7.6k38.4k27.0k46.7k83.3k62.4k78.1k113.6k102.3k90.0k112.4k210.0k232.0k306.0k259.0k

Prepaid Expenses

1.3k1.3k3.6k3.6k45.0k45.0k45.0k45.0k45.0k55.4k92.5k43.9k32.3k147.4k12.8k41.6k32.7k56.6k60.2k34.0k25.0k105.0k44.0k

Inventories

67.4k69.4k63.3k54.9k52.3k52.1k40.9k35.9k33.7k24.7k62.7k20.5k14.6k12.7k32.0k23.9k25.6k24.6k36.9k39.3k56.8k25.6k46.2k26.0k38.0k19.0k33.0k

Current Assets

320.0k270.8k391.7k582.3k487.4k151.5k127.2k94.2k446.5k391.0k264.0k300.4k164.1k666.7k1.2m1.0m1.9m1.4m561.3k1.4m1.1m823.3k752.3k782.0k1.0m2.6m1.1m

PP&E

5.4k4.0k1.4k1.1k741.05.4k55.0k54.1k50.3k55.2k117.3k122.4k125.2k110.0k108.0k106.0k63.0k

Total Assets

325.4k301.1k447.7k638.0k542.8k200.6k173.6k138.0k484.7k426.5k296.9k383.2k264.1k767.7k1.2m1.0m2.0m1.5m643.0k1.7m1.5m1.2m1.1m3.4m3.6m5.1m3.6m

Accounts Payable

533.7k750.0k991.6k945.1k927.9k472.9k648.1k401.3k358.7k331.3k420.9k512.1k444.0k275.6k257.5k293.1k290.1k57.4k158.7k277.4k273.8k149.3k242.1k370.0k328.0k297.0k430.0k

Short-term debt

100.0k100.0k100.0k100.0k100.0k100.0k100.0k100.0k50.0k50.0k50.0k383.0k283.0k50.0k4.9m4.9m5.8m782.2k1.4m920.0k964.0k275.0k3.8m

Current Liabilities

2.1m2.3m1.8m1.6m1.6m681.7k748.1k501.3k508.7k481.3k622.6k791.2k709.6k400.6k357.5k411.1k831.2k696.8k3.7m3.6m5.1m943.5k1.8m3.1m4.5m4.8m4.7m

Long-term debt

513.8k513.8k100.0k100.0k100.0k50.0k50.0k50.0k2.2m300.0k50.0k175.0k925.6k1.5m1.8m1.3m890.0k1.5m464.0k925.0k814.0k

Non-Current Liabilities

301.6k377.0k5.6k39.7k109.9k2.1m1.0m1.4m

Total Debt

100.0k100.0k100.0k613.8k613.8k200.0k200.0k200.0k50.0k50.0k50.0k383.0k283.0k250.0k3.5m300.0k50.0k610.0k9.7m50.0k11.2m2.0m2.3m3.0m3.5m6.1m4.7m

Total Liabilities

2.3m2.6m2.2m1.6m1.6m681.7k748.1k501.3k508.7k481.3k622.6k835.2k749.3k510.6k972.6k1.5m2.1m3.1m4.1m4.1m6.1m1.8m2.1m5.2m5.5m6.1m6.2m

Common Stock

37.5k38.1k40.9k43.7k44.5k47.8k48.5k49.4k53.2k53.9k54.7k55.6k56.1k57.1k57.6k58.2k60.1k63.5k66.9k68.2k71.4k86.2k88.6k97.0k102.0k106.0k119.0k

Preferred Stock

Additional Paid-in Capital

63.8m64.2m66.6m69.2m70.0m72.9m73.5m74.4m76.4m77.3m77.8m79.3m80.4m83.0m85.1m86.2m88.9m91.8m92.5m95.8m98.6m106.2m108.2m112.6m114.7m119.4m123.1m

Retained Earnings

(65.8m)(66.6m)(68.4m)(70.2m)(71.1m)(73.4m)(74.0m)(74.7m)(76.3m)(77.4m)(78.3m)(79.8m)(81.0m)(82.8m)(85.7m)(87.3m)(89.7m)(93.9m)(96.3m)(98.9m)(103.8m)(107.3m)(109.6m)(114.6m)(116.9m)(120.6m)(125.9m)

Total Equity

(2.0m)(2.3m)(1.7m)(938.2k)(1.1m)(481.0k)(574.5k)(363.3k)(23.9k)(54.8k)(325.8k)(413.7k)(485.2k)257.2k217.6k(428.3k)(160.1k)(1.6m)(3.5m)(2.4m)(4.6m)(644.5k)(980.9k)(1.8m)(1.9m)(1.0m)(2.6m)

Debt to Equity Ratio

-2.1 x-0.9 x-0.2 x-0.6 x1 x16.1 x-0.3 x-0.4 x-2.8 x0 x-2.4 x-3 x-1.7 x-1.8 x-6.1 x

Debt to Assets Ratio

0.1 x0.1 x0.2 x1.1 x0.3 x2.9 x0 x0.4 x15.1 x0 x7.7 x1.7 x0.9 x1 x1.2 x

Financial Leverage

-0.2 x-0.1 x-0.3 x-0.7 x-0.5 x-0.4 x-0.3 x-0.4 x-20.3 x-7.8 x-0.9 x-0.9 x-0.5 x3 x5.5 x-2.4 x-12.3 x-0.9 x-0.2 x-0.7 x-0.3 x-1.8 x-1.1 x-1.9 x-1.9 x-5.1 x-1.3 x

BioLargo Cash Flow

Quarterly

USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020

Net Income

(2.3m)(3.0m)(921.0k)(2.7m)(3.6m)(645.3k)(1.2m)(2.2m)(1.1m)(2.1m)(3.0m)(786.2k)(2.0m)(3.8m)(1.6m)(2.1m)(4.6m)(7.1m)(2.4m)(6.0m)(8.4m)(2.7m)(4.7m)(8.6m)(2.6m)

Depreciation and Amortization

5.2k6.5k1.3k1.6k2.0k2.7k5.5k8.2k2.7k5.5k8.2k2.7k5.5k8.2k2.7k5.6k8.6k7.9k14.4k21.1k10.3k22.9k36.3k16.0k31.0k48.0k16.0k

Accounts Receivable

(8.7k)7.3k1.6k(3.2k)3.2k(3.3k)10.3k458.0(1.0k)(778.0)(1.8k)(1.9k)(32.8k)14.4k(5.3k)(41.9k)(9.4k)(25.1k)(48.1k)(7.9k)3.4k(19.0k)47.0k24.0k(72.0k)96.0k

Inventories

59.5k1.4k(6.9k)(9.5k)1.9k13.0k18.1k3.9k(5.1k)(32.8k)5.0k10.9k12.8k5.5k13.6k11.8k9.8k(2.5k)(4.8k)(2.8k)28.3k7.8k(12.0k)7.0k(17.0k)

Accounts Payable

170.9k286.9k387.1k396.4k144.1k328.3k126.1k(44.1k)(26.9k)65.3k12.6k(43.1k)(224.0k)(60.1k)(13.8k)(62.7k)36.6k144.3k345.8k126.9k30.6k142.1k129.0k178.0k88.0k210.0k

Cash From Operating Activities

(1.0m)(1.3m)(379.0k)(1.1m)(1.7m)(465.2k)(827.5k)(991.2k)(556.6k)(1.0m)(1.4m)(274.5k)(813.4k)(1.3m)(986.5k)(1.7m)(2.8m)(1.2m)(2.0m)(3.1m)(995.6k)(2.1m)(3.1m)(869.0k)(1.9m)(3.2m)(753.0k)

Purchases of PP&E

(3.7k)(3.7k)(18.8k)

Cash From Investing Activities

(3.7k)(3.7k)(5.5k)(55.3k)(9.0k)(18.8k)(26.4k)(42.7k)(14.0k)(27.0k)(84.0k)

Short-term Borrowings

20.0k20.0k

Cash From Financing Activities

823.5k1.1m561.1k1.5m2.0m405.0k744.0k893.5k827.5k1.2m1.5m347.5k755.9k1.7m255.0k835.0k2.8m453.0k588.0k2.4m938.2k1.7m2.6m730.0k1.9m4.7m926.0k

Net Change in Cash

(181.3k)(235.4k)182.1k386.8k299.3k(60.2k)(83.5k)(97.7k)270.9k225.9k59.2k73.0k(57.5k)405.7k(740.8k)(874.1k)(31.2k)(734.6k)(1.5m)(658.2k)(68.5k)(339.4k)(456.9k)(143.0k)51.0k1.5m89.0k

Interest Paid

6.7k6.7k4.7k9.4k13.8k4.5k6.7k5.5k5.5k32.0k40.0k116.0k25.0k

Income Taxes Paid

2.4k3.7k4.3k2.8k2.8k400.02.4k2.4k4.0k4.0k4.0k4.0k6.5k5.4k5.4k5.4k5.7k5.7k3.0k3.0k3.0k2.0k

BioLargo Ratios

USDQ2, 2011

Financial Leverage

-0.2 x